Their nanocomposite hydrogel delivered an NADPH oxidase 4 (Nox4) inhibitor followed by doxorubicin, reprogramming the stromal environment and boosting Anti-Programmed Cell Death Protein 1 (PD–1) responses in osteosarcoma models [109]. This evidence concerns the gene PDCD1 and osteosarcoma.